VivoSeq
Oncology

Lung Carcinoma

24

Pipeline Programs↗

13

Active Trials↗

18

Companies Involved↗

Lung Carcinoma is an emerging landscape with 24 programs across 18 companies. The most active players are Chongqing Precision Biotech Co., Ltd, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Bristol-Myers Squibb. 6 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

25/100

Mech. Concentration

15/100

Completion Rate

83/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chongqing Precision Biotech Co., Ltd

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 2Moderna logo

Moderna

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

20 of 25 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody312%RNA therapy14%Cell therapy14%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 96% of 28 pipeline programs.

Analysis

Trial Status

20

clinical trials

Recruiting9 · 45%
Completed5 · 25%
Not yet recruiting3 · 15%
Terminated1 · 5%
Unknown status1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06903117·60 enrolled
Integrating Restorative Practices to Enhance Shared Decision-Making and Uptake of Lung Cancer Screening in Black Community Members (RESTORE)
Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07490860·45 enrolled
T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study
Recruiting·CCentral South University·N/A·NCT07066813·500 enrolled
Effect of a Music Intervention in Reducing Distress and Pain in Patients With Suspected or Diagnosed Lung Cancer Undergoing Mini-Invasive Surgery
Recruiting·OOncology Institute of Southern Switzerland·Preclinical·NCT07235098·74 enrolled
Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes
Recruiting·CCentral South University·N/A·NCT06699979·300 enrolled
Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based
Recruiting·—·Preclinical·NCT07682597·200 enrolled
Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System (Kentucky QUILS™ Implementation): HSR Intervention
Recruiting·—·Preclinical·NCT07682610·35,500 enrolled
Statewide Optimization of Lung Cancer Screening Utilizing the QUILS System
Recruiting·—·Preclinical·NCT07639255·330 enrolled
Improving Decision-Making Encounters in Lung Cancer (I DECide) II: A Randomized Control Trial Of A Low-Literacy Conversation Tool
Recruiting·OOHSU Knight Cancer Institute·Preclinical·NCT05407168·300 enrolled
The Potential Risks and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05144542·140 enrolled
Strengthening Awareness and Community Resources for Early Detection of Lung Cancer Through Navigation Guided Screening Trial (SACRED LUNGS Aims 1.2-3)
Not yet recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07176000·237 enrolled
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A
Not yet recruiting·MMassachusetts General Hospital·Preclinical·NCT07685028·250 enrolled
Effects of Respiratory Muscle Training and Aerobic Exercise on Lung Health in Smokers: A Pilot Parallel-Group Study for Lung Cancer Prevention
Not yet recruiting·RRoswell Park Cancer Institute·Preclinical·NCT07553819·200 enrolled
Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
Completed·Sanofi logoSanofi·Phase 2·NCT00777179·117 enrolled
Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
Completed·HHellenic Oncology Research Group·Phase 3·NCT00430651·135 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)